Analysis of serious adverse drug events in elderly patients using sodium-glucose cotransporter-2 inhibitor based on FAERS
Objective:To analyze the serious adverse drug events of sodium-glucose cotransporter-2 inhibitors(SGLT-2i)in elderly patients thus to provide reference for safe medication in elderly patients.Methods:The adverse drug event reports of SGLT-2i as first suspected drugs recorded in the FAERS database were mined,and chi-square test was used to analyze the differences in the incidence and outcome between elderly and non-elderly patients.Results:A total of 25 416 reports with clear age records were extracted in this study,of which 10 605 reports were from elderly patients.Except for the negative signal of acute kidney injury caused by empagliflozin in elderly patients,all other signals were positive.The probability of serious ADE occurring in elderly patients using canagliflozin was significantly lower than that in non-elderly patients.In terms of the probability of death or life-threatening outcomes in elderly patients due to serious ADE,empagliflozin>dapagliflozin>canagliflozin.Conclusion:The incidences of four serious ADE and the probability of death or life-threatening outcomes caused by canagliflozin in elderly patients are the lowest,while those for empagliflozin are the highest.It is recommended to conduct in-depth research on the adverse drug reactions of SGLT-2i in elderly patients in clinical practice,in order to provide reference for safe medication.
FDA adverse event reporting systemelderly patientssodium-glucose cotransporter-2 inhibitorserious adverse drug events
NETL
NSTL
万方数据
